Patient Adherence and Tolerability Profiles of AntiSeizure Drug (ASD) Use in Bipolar disorder

Abstract
Bipolar Disorder is a complex and recurrent mental health condition characterized by extreme
mood swings, including manic and depressive episodes. Anticonvulsants have emerged as vital
components in the pharmacological management of bipolar disorder, particularly for patients
exhibiting rapid cycling and mixed features.The treatment of bipolar disorder often involves the use
of anticonvulsants, which are increasingly recognized for their efficacy in mood stabilization. This
abstract reviews the adherence and safety profiles associated with anticonvulsant use in this patient
population, synthesizing findings from recent clinical studies and metaanalyses. Anticonvulsants
such as valproate,carbamazepine and lamotrigine have demonstrated effectiveness in reducing the
frequency of manic and depressive episodes in patients. However, medication adherence remains a
significant challenge due to factors such as side effects, complex dosing regimens, and comorbid
conditions. Research indicates that approximately 3050% of patients may struggle with consistent
adherence, adversely impacting treatment outcomes. The safety profiles of these medications are
critical, as they can lead to side effects. This review highlights the importance of ongoing patient
education, regular monitoring, and the establishment of therapeutic alliances to improve adherence
rates. By addressing the challenges surrounding adherence and recognizing the diverse safety
profiles of anticonvulsants, clinicians can enhance therapeutic effectiveness and improve overall
patient wellbeing. Continued research is vital to develop tailored strategies that optimize treatment
regimens for individuals living with bipolar disorder.In conclusion, anticonvulsants are a valuable
therapeutic option in the management of bipolar disorder, warranting continued investigation to
enhance clinical outcomes.

KEYWORDS : Bipolar disorder, Anticonvulsant, mood satibilization,carbamazepine, sodium
valproate